Related Experiment Video
Updated: May 27, 2026
07:08
A High Throughput, Multiplexed and Targeted Proteomic CSF Assay to Quantify Neurodegenerative Biomarkers and Apolipoprotein E Isoforms Status
Published on: October 20, 2016
Biomarkers for delirium--a review
Babar A Khan1, Mohammed Zawahiri, Noll L Campbell
1Division of Pulmonary and Critical Care, Department of Medicine, School of Medicine, Indiana University, Indianapolis, USA. bakhan@iupui.edu
Journal of the American Geriatrics Society
|November 19, 2011
Summary
Current serum biomarkers show limited clinical utility for delirium management. While some markers like S-100 beta and IGF-1 are promising, further research is needed to validate their use in diverse populations.
Area of Science:
- Geriatric Medicine
- Neuroscience
- Biomarker Research
Background:
- Delirium recognition and care require improved tools.
- Serum biomarkers are explored for delirium risk stratification, diagnosis, monitoring, and prognostication.
Purpose of the Study:
- To review the current evidence for serum biomarkers in delirium.
- To assess the clinical utility of investigated biomarkers.
Main Methods:
- Comprehensive literature review of studies investigating serum biomarkers for delirium.
Main Results:
- No current serum biomarker is supported by evidence for clinical use in delirium.
- Certain biomarkers, including S-100 beta, insulin-like growth factor-1, and inflammatory markers, show preliminary promise.
Conclusions:
- Existing delirium biomarkers lack sufficient evidence for clinical application.
- Future research should focus on large-scale, prospective studies with generalizable populations to validate promising biomarkers.
Related Concept Videos
01:26Alzheimer's Disease: Overview
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
01:22Dementia l: Introduction
Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...
01:30Dementia
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual.
The progression of dementia is generally gradual.